Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

SMC

- PMLiVE

AbbVie deal with Amgen sets biosimilar Humira launch dates

Agreement will see Europe access the drug over four years earlier than patients in the US

- PMLiVE

FDA wants more data on J&J’s arthritis drug Plivensia

Requests further evidence on the drug’s safety profile after patient deaths link

- PMLiVE

AbbVie and Roche plan Venclexta combo filings in leukaemia

MURANO trial shows the duo’s treatment extends PFS

- PMLiVE

New EU and US approvals for Humira biosimilars

Samsung’s Imraldi and Boehringer Ingelheim’s Cyltezo receives nod from EMA and FDA, respectively

- PMLiVE

SMC gives green light for Amgen’s Kyprolis

The committee also gives verdict on three other products

- PMLiVE

SMC gives green light for Amgen’s Kyprolis

The committee also gives verdict on three other products

Sanofi reception

Sanofi and Regeneron bag EU approval for arthritis drug Kevzara

The IL-6 inhibitor will be used in combination with methotrexate for adults with RA

- PMLiVE

Samsung Bioepis wins CHMP nod for second Humira biosimilar

In addition to Imraldi the regulatory advisors also backed new medicines from AbbVie and Gilead

- PMLiVE

Lilly and NRAS launch arthritis awareness film campaign

Pharma firm's ‘Behind The Smile’ initiative coincides with RA awareness week

- PMLiVE

AbbVie appoints new GMs for France and the UK

Jérôme Bouyer and Pierre-Claude Fumoleau take up new roles at the pharma firm

EU flag

CHMP backs two rare disease therapies at April meeting

Biogen's Spinraza and BioMarin's Brineura near EU approval

- PMLiVE

AbbVie’s PARP inhibitor veliparib fails to deliver

Phase III trials show no increase in clinical benefit

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links